Filing summary
Period and entity discrepancy: The request identifies GT Biopharma, Inc. and 2013 Q2, but the supplied filing is for OXIS International, Inc. and the quarter ended June 30, 2014, with six-month results through that date. It was signed January 8, 2015. The summary below reflects the supplied filing, not the requested company or period.
Business context and reporting period
OXIS describes its business as developing and selling or licensing products related to oxidative stress and inflammation, with a focus on ergothioneine-based nutraceuticals and related products. It reported minimal product sales, no license revenue, and no research and development expense during the six months ended June 30, 2014.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | 2014: $25,000; 2013: $56,000 | 2014: $25,000; 2013: $144,000 |
| Gross profit | 2014: $8,000; 2013: $44,000 | 2014: $8,000; 2013: $63,000 |
| Operating expenses | 2014: $112,000; 2013: $118,000 | 2014: $213,000; 2013: $484,000 |
| Net income (loss) | 2014: $(262,000); 2013: $(306,000) | 2014: $(633,000); 2013: $162,000 |
| Operating cash flow | Not separately presented | 2014: $(133,000); 2013: $(118,000) |
- Six-month revenue fell $119,000, or about 83%. Gross margin was about 32% in 2014 versus 44% in 2013; quarterly gross margin was about 32% versus 79%.
- Six-month interest expense was $365,000, down from $787,000. The change in warrant and derivative liability value was a $61,000 expense in 2014, compared with $1.375 million of income in 2013; this was a major factor in the shift from prior-year net income to a loss.
- At June 30, cash was $1,000, total assets $52,000, current liabilities $6.861 million, total liabilities $7.017 million, and stockholders’ deficit $6.965 million. Accumulated deficit was $90.1 million. Management reported a $6.829 million working-capital deficit.
- Financing activities provided $89,000 in the first half, including proceeds from short-term borrowings. Cash declined $42,000 from $43,000 at year-end 2013. The company reported four promissory notes totaling $89,000 during the period.
- Current liabilities included accrued interest of $1.787 million, accounts payable of $925,000, accrued expenses of $1.251 million, and convertible debt and notes. The filing describes multiple overdue/defaulted debt arrangements; the complete debt terms and amounts are detailed across the notes.
Changes, outlook, and risks
- Management attributed the decline in selling, general and administrative expenses mainly to lower non-cash fees. It said sales data was not considered indicative of future operations and that it was evaluating product marketability.
- The filing states that cash usage raises substantial doubt about the company’s ability to continue as a going concern. Management planned to seek further equity or debt financing and increase revenues, but gave no assurance that financing or product revenue would be obtained. No quantified operating guidance was provided.
- Subsequent events disclosed a July 2014 sale of $1.25 million of 10% convertible debentures with warrants, and additional $1.25 million of convertible debenture investment proceeds in October 2014. These events occurred after the reporting date and do not change June 30 cash.
- After quarter-end, the company reported board and executive changes, formation of Oxis Biotech to pursue cannabinoid-related opportunities, and an October 2014 resolution of a licensing-rights dispute. Under the reported resolution, OXIS was to receive a cash payment and perpetual royalty on future product sales; the filing text does not provide a clear amount.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2014, citing inadequate segregation of duties and risk of executive override due to a small staff and reliance on consultants.
- Potential dilution is substantial: 563.2 million warrants were outstanding at June 30, and the filing reports 592.5 million potentially dilutive shares excluded from loss-per-share calculations. Common shares outstanding were 573.1 million.
Investor verification points
- Confirm that the intended filing is OXIS International’s June 30, 2014 Form 10-Q, rather than a GT Biopharma filing for 2013 Q2.
- Review the going-concern warning, near-term cash needs, financing terms, debt defaults, and any creditor rights against company assets.
- Verify the extent of dilution from convertible debt, warrants, options, and preferred stock, including conversion prices and share authorization limits.
- Check the subsequent financing proceeds, executive and board changes, and the consideration and accounting for the licensing-dispute resolution.
- Assess the disclosed material weaknesses in financial reporting controls and whether remediation occurred.